Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Unknown Analyst

Good morning, everybody. Welcome to the Bank of America Healthcare Conference, our London version. I’m pleased to be kicking off the conference with our first presenting company, Vertex. Presenting for Vertex and sitting next to me is Senior Vice President of Investor Relations, Susie Lisa. Susie, good morning. Thanks for flying over from Boston.

Susie Lisa
Senior Vice President of Investor Relations

Thanks for having me.

Unknown Analyst

So I think everybody in the room is quite familiar with Vertex as a company, so we don’t need to do the 2-minute elevator pitch. But I think it would be good to get a sense of what catalysts are upcoming for the company in general, let’s say, for the next 12 to 18 months, and then we can go into a little bit more detail on some of those.

Susie Lisa
Senior Vice President of Investor Relations

Sounds good. And thanks again for having me. So I think as usual, at Vertex, there is a lot going on. And maybe first and foremost, in terms of catalysts, I’d point to 3 ongoing commercial launches, right, as we enter into this new phase of revenue and commercialization diversification. So gauging the launches for ALYFTREK, our fifth medicine in cystic fibrosis, CASGEVY for sickle cell disease and beta-thalassemia and for JOURNAVX in acute pain.

And then beyond that, we have 4 ongoing Phase III programs and a fifth to start soon. So just to run through those, and then I’ll get to the catalysts within them. It’s Phase III programs for diabetic peripheral neuropathy in our pain franchise for 3 in the kidney space, 2